Cell Therapy Manufacturing Market, 2027: Partnerships / Collaborations have been Widespread and will Continue to act as Key Enablers

Dublin, March 28, 2017 -- Research and Markets has announced the addition of the "Cell Therapy Manufacturing Market, 2017-2027" report to their offering.

During the course of our study, we identified over 110 organizations that are actively involved in the manufacturing of cell therapies.

The scope of this report primarily includes manufacturing of advanced therapy medicinal products (ATMPs) that involve the use of immune cells such as T-cells, Tregs, dendritic cells, tumor cells and NK cells, and stem cells such as adult stem cells, human embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs).

Several players, including cell therapy developers, research institutes, contract manufacturing organizations, and government and non-profit organizations, are playing a critical role in the development and manufacturing of these cell therapies. In fact, a number of these players have made heavy investments to expand their existing capabilities and establish new facilities for cell therapy products in order to meet the increasing demand.

Additionally, stakeholders have received significant support from governments worldwide, in terms of funding and establishment of consortiums to accelerate the transition of these therapies from laboratories to clinics. It is important to highlight that companies that offer logistics and operational services have developed systems / tools for safer and quicker delivery of therapies from manufacturing sites to patients; this has been identified as one of the key challenges in the overall development process.

Popular examples of approved cell-based therapies include (in order of their year of approval) Carticel®, CreaVax-RCC®, JACE, ReliNethra, PROVENGE® and Prochymal®. In addition, over 500 cell-based therapy candidates are currently in different stages of clinical development; these are being evaluated in over 1,000 active clinical studies in various regions across the globe. The growing number of cell therapy candidates, coupled with their rapid progression through the various phases of clinical development, continues to create an increasing demand for facilities that offer manufacturing services for these therapies.

The market already has a wide array of well-established players, mid-sized companies and start-ups. Several industry players as well as academic institutes are significantly contributing to the production of GMP grade cell types. In addition, the market has witnessed the entry of several players that offer novel technology solutions, aimed at improving and upgrading existing cell-based therapies and their manufacturing processes. We have observed that such players have signed multiple partnerships / collaborations with an aim to optimize, scale-up and expand the capabilities for production of cell-based therapies.

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. CELL THERAPY MANUFACTURING: INTRODUCTION
3.1. Context and Background
3.2. Cell-based Therapies: Introduction
3.3. Cell Therapy Manufacturing: An Introduction
3.4. Cell-based Therapies Manufacturing: Key Challenges
3.5. Cell Therapy Manufacturing: Types of Manufacturers
3.6. Cell Therapy Manufacturing: Other Important Considerations
3.7. Cell Therapy Manufacturing: Regulatory Landscape

4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Cell Therapy Manufacturing: Overall Market Landscape
4.3. Cell Therapy Manufacturing: Role of Logistic Service Providers

5. ROADMAPS: POTENTIAL STRATEGIES TO OVERCOME EXISTING CHALLENGES
5.1. Chapter Overview
5.2. Roadmap for the United States
5.3. Roadmaps for Other Geographies

6. CELL THERAPY MANUFACTURING: IN-HOUSE MANUFACTURERS
6.1. Chapter Overview
6.2. Argos Therapeutics
6.3. Bavarian Nordic
6.4. Cytori Therapeutics
6.5. Juno Therapeutics
6.6. MEDIPOST
6.7. SOTIO (Acquired by PPF Group)
6.8. Stemedica Cell Technologies

7. CELL THERAPY MANUFACTURING: INDUSTRY PLAYERS
7.1. Chapter Overview
7.2. Cell and Gene Therapy Catapult
7.3. CELLforCURE
7.4. Lonza
7.5. PharmaCell
7.6. PCT, a Caladrius Company
7.7. Roslin Cell Therapies
7.8. Waisman Biomanufacturing

8. CELL THERAPY MANUFACTURING: NON-INDUSTRY PLAYERS
8.1. Chapter Overview
8.2. Center for Cell and Gene Therapy, Baylor College of Medicine, US
8.3. Centre for Cell Manufacturing Ireland, National University of Ireland, Ireland
8.4. Clinical Cell and Vaccine Production Facility, University of Pennsylvania, US
8.5. Guy's And St. Thomas' GMP Facility, Guy's Hospital, UK
8.6. Newcastle Cellular Therapies Facility, Newcastle University, UK
8.7. Rayne Cell Therapy Suite, King's College London, UK
8.8. Scottish National Blood Transfusion Services Cellular Therapy Facility, Scottish Centre of Regenerative Medicine, UK
8.9. Laboratory of Cell and Gene Medicine, Stanford University, US

9. ROLE OF NON-PROFIT ORGANIZATIONS
9.1. Chapter overview
9.2. Cell Therapy Manufacturing: List of Non-Profit Organizations
9.3. Cell Therapy Manufacturing: International Societies

10. RECENT DEVELOPMENTS
10.1. Chapter Overview
10.2. Collaboration / Agreement Models
10.3. Cell Therapy Manufacturing: List of Collaborations
10.4. Cell Therapy Manufacturing: Partnership Analysis

11. MARKET SIZING AND FORECAST
11.1. Context and Background
11.2. Forecast Methodology
11.3. Cell Therapy Manufacturing Market, 2017-2027
11.4. Cell Therapy Manufacturing Market: Regional View

12. SWOT ANALYSIS

13. CONCLUSION
13.1. A Growing Pipeline of Cell Therapy Products is Likely to Increase the Demand for Manufacturing of Cell-based Therapies
13.2. Stakeholders are Continuously Striving to Overcome Existing Challenges
13.3. Developed Economies have Emerged as Prominent Hubs for Cell Therapy Manufacturing
13.4. Both Industry and Academia have Jointly Led the Initiatives; The Trend is Likely to Persist in the Near Term
13.5. Partnerships / Collaborations have been Widespread and will Continue to act as Key Enablers
13.6. The Manufacturing of Cell-based Therapies is Likely to Become a Multi-billion Dollar Market in the Coming Decade

14. SURVEY ANALYSIS
14.1. Chapter Overview
14.2. Seniority Level of Respondents
14.3. Type of Cell Therapy
14.4. Scale of Operation
14.5. Source of Cells
14.6. Type of Cell Culture System
14.7. Fill / Finish Service

15. INTERVIEW TRANSCRIPTS
15.1. Chapter Overview
15.2. Tim Oldham, CEO, Cell Therapies
15.3. Brian Dattilo, Manager of Business Development, Waisman Biomanufacturing
15.4. Mathilde Girard, Department Leader, Cell Therapy Innovation and Development, YposKesi
15.5. Dr. Gerard J Bos (CEO, CiMaas)

16. APPENDIX: TABULATED DATA

17. APPENDIX: LIST OF COMPANIES AND RESEARCH ORGANIZATIONS

For more information about this report visit http://www.researchandmarkets.com/research/bvlctq/cell_therapy

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Genomics